Based in Paris, France, Gleamer serves over 700 customer contracts worldwide with a broad portfolio of FDA-cleared and CE-marked solutions for musculoskeletal, breast, lung and neurologic applications.

总部位于法国巴黎的 Gleamer 拥有覆盖肌肉骨骼、乳腺、肺部和神经应用的广泛 FDA 认证和 CE 标志解决方案，为全球超过 700 份客户合同提供服务。

Gleamer’s leadership in routine imaging, and particularly X-ray, is unparalleled

Gleamer在常规成像，尤其是X射线方面的领导地位是无与伦比的。

through the breadth and scale of its cloud-first AI solutions.

通过其云优先的AI解决方案的广度和规模。

DeepHealth, combined with Gleamer’s solutions will provide the industry’s most comprehensive portfolio of native clinical AI solutions and services across all core imaging modalities.

DeepHealth与Gleamer的解决方案相结合，将提供业内最全面的原生临床AI解决方案和服务，覆盖所有核心成像模式。

Gleamer achieved an Annual Recurring Revenue (“ARR”)

Gleamer 实现了年度经常性收入（“ARR”）

i

我

compound annual growth rate exceeding 90% from 2022 through 2025 and is expected to reach approximately $30 million ARR in 2026.

复合年增长率从2022年到2025年超过90%，预计到2026年将达到约3000万美元的年度经常性收入（ARR）。

The acquisition will augment DeepHealth’s global commercial sales force and add a strong research and development team who have developed, commercialized and delivered solutions to support over 25 clinical indications.

此次收购将增强DeepHealth的全球商业销售团队，并增加一支强大的研发团队，该团队曾开发、商业化并交付了支持超过25种临床适应症的解决方案。

Deploying Gleamer’s solutions should drive cost efficiencies and improve patient care within RadNet by the third quarter of 2026.

到2026年第三季度，部署Gleamer的解决方案应会推动RadNet的成本效率并改善患者护理。

LOS ANGELES and PARIS, March 02, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet”), a U.S. leader in outpatient diagnostic imaging services, announced today it has acquired Gleamer SAS (“Gleamer”), a leading radiology AI company based in Paris, France, to be integrated into DeepHealth, RadNet’s wholly owned subsidiary.

洛杉矶和巴黎，2026年3月2日（环球新闻社）-- 美国领先的门诊诊断成像服务提供商RadNet公司（纳斯达克股票代码：RDNT）（“RadNet”）今日宣布，已收购总部位于法国巴黎的领先放射学AI公司Gleamer SAS（“Gleamer”），并将将其整合到RadNet的全资子公司DeepHealth中。

The acquisition further expands DeepHealth’s AI-powered health informatics solutions and services, making it the largest provider of radiology clinical AI solutions worldwide..

此次收购进一步扩展了DeepHealth的AI驱动的健康信息学解决方案和服务，使其成为全球最大的放射学临床AI解决方案提供商。

ii

二

With more than 130 professionals, Gleamer is a fast growing, cloud-first, radiology AI company serving more than 700 customer contracts in 44 countries in Europe and beyond. Its broad multimodality portfolio of FDA-cleared and CE-marked clinical AI and workflow solutions for musculoskeletal, breast, lung and neurologic applications is designed to improve quality of care while reducing the radiologist workload.

Gleamer是一家快速成长、以云技术为先的放射学AI公司，拥有130多名专业人员，为欧洲及其他44个国家的700多份客户合同提供服务。其广泛多模态的产品组合包括经FDA批准和CE认证的肌肉骨骼、乳腺、肺部及神经应用的临床AI和工作流程解决方案，旨在提高护理质量的同时减轻放射科医生的工作负担。

Gleamer’s customers include hospitals, imaging centers and healthcare systems, and its cloud platform drives a SaaS ARR business model..

Gleamer 的客户包括医院、影像中心和医疗保健系统，其云平台推动了 SaaS ARR 商业模式。

Dr. Howard Berger, President and CEO of RadNet, commented: “As imaging volumes continue to rise amid an accelerating shortage of radiologists worldwide, reengineering high-volume workflows — particularly routine imaging such as X-ray, ultrasound and mammography — is becoming essential to sustaining access, efficiency and quality of care.

RadNet总裁兼首席执行官霍华德·伯杰博士评论道：“随着全球范围内放射科医生短缺的情况日益加剧，成像量持续上升，重新设计高流量工作流程——尤其是如X光、超声和乳腺摄影等常规成像——对于维持医疗的可及性、效率和质量变得至关重要。”

For radiologists and providers, the key lies in advancing automated exam prioritization and draft reporting. The acquisition of Gleamer uniquely positions DeepHealth to expand its impact across routine imaging and high-impact acute diagnostic care and accelerate the delivery of automated diagnostics.”.

对于放射科医生和医疗服务提供者来说，关键在于推进自动化的检查优先级排序和初步报告生成。收购Gleamer使DeepHealth能够独特地扩展其在常规影像和高影响力的急性诊断护理中的影响力，并加速自动化诊断的交付。

The integration of Gleamer’s portfolio with DeepHealth’s clinical AI suites of solutions for breast, chest, neuro, prostate and thyroid creates a comprehensive portfolio unrivalled by any other radiology AI company. The combined portfolio supports screening, detection, interpretation and follow-up across many of the most prevalent cancer types, as well as neurodegenerative and musculoskeletal conditions, including trauma and chronic conditions.

将Gleamer的产品组合与DeepHealth针对乳腺、胸部、神经、前列腺和甲状腺的临床AI解决方案套件相结合，打造出一个在放射学AI公司中无与伦比的全面产品组合。该组合支持多种最常见癌症类型的筛查、检测、解读和随访，同时还涵盖神经退行性疾病和肌肉骨骼疾病，包括创伤和慢性病。

With the inclusion of Gleamer’s products, DeepHealth is now the worldwide leader in clinical AI solutions across MR, CT, X-ray, Mammography and Ultrasound modalities..

随着Gleamer产品的加入，DeepHealth现已成为横跨核磁共振、CT、X射线、乳腺摄影和超声波等模态的全球临床AI解决方案领导者。

“Joining DeepHealth marks an exciting new chapter for our business and team members,” said Christian Allouche, Co-Founder and CEO of Gleamer. “Our team has been driven by a mission to improve patient care and access, and we are proud of the impact we have had on our customers and patients worldwide.

“加入DeepHealth标志着我们的业务和团队成员迎来了令人兴奋的新篇章，”Gleamer的联合创始人兼首席执行官克里斯蒂安·阿鲁什表示。“我们的团队一直致力于改善患者护理和获取途径，我们为在全球范围内对客户和患者产生的影响感到自豪。

By combining our AI capabilities, product portfolio and strong commercial team with that of DeepHealth, we are poised to shape the future of intelligent imaging at scale.”.

通过将我们的AI能力、产品组合和强大的商业团队与DeepHealth相结合，我们有望大规模塑造智能成像的未来。

“We welcome Gleamer’s team and capabilities into DeepHealth,” said Kees Wesdorp, President and CEO of RadNet’s Digital Health Division, DeepHealth. “This acquisition brings together two leaders on strong growth trajectories to create a new standard of AI-powered care. By building on our combined strengths, we are redefining how imaging is delivered, at scale, with intelligence and automation, to advance access and efficiency while improving experiences and outcomes for patients and providers worldwide.”.

“我们欢迎Gleamer的团队和能力加入DeepHealth，”RadNet数字健康部门DeepHealth的总裁兼首席执行官Kees Wesdorp表示。“此次收购将两位处于强劲增长轨道上的领导者结合在一起，开创了一个人工智能驱动护理的新标准。通过发挥我们的综合优势，我们正在重新定义医学影像的交付方式，在大规模、智能化和自动化的前提下推进获取途径和效率，同时改善全球患者和医疗服务提供者的体验与结果。”

Gleamer’s capabilities in automated reporting, already deployed in Europe, combined with DeepHealth’s AI and informatics portfolio, bring clinical, generative and agentic AI and imaging informatics together into an integrated offering. With this extensive expertise, DeepHealth is uniquely positioned to enable more standardized interpretation, automated draft reporting and scalable diagnostic pathways..

Gleamer在欧洲已经部署的自动化报告功能，与DeepHealth的AI和信息学产品组合相结合，将临床、生成式和代理式AI以及影像信息学整合到一个综合服务中。凭借这一广泛的专业知识，DeepHealth能够以独特的优势实现更标准化的解读、自动生成报告草稿以及可扩展的诊断路径。

Additionally, deploying Gleamer’s radiology AI and workflow capabilities across RadNet’s imaging network is expected to create measurable productivity gains, particularly in X-ray, which accounts for almost 25% of RadNet’s imaging volume. RadNet intends to implement an end-to-end AI-enabled workflow that begins with triaging critical findings to accelerate the interpretation of the most urgent cases.

此外，将 Gleamer 的放射学 AI 和工作流程功能部署到 RadNet 的影像网络中，预计将带来可衡量的生产力提升，尤其是在 X 射线领域，该领域占 RadNet 影像总量的近 25%。RadNet 计划实施一个端到端的 AI 驱动工作流程，首先对危急发现进行分诊，以加快对最紧急病例的解读。

The acquisition will also accelerate the introduction of draft reporting capabilities, allowing radiologists to increase reading volumes with greater accuracy and standardization. This approach will enable RadNet to optimize internal resource utilization, resulting in improved operational and cost efficiencies..

此次收购还将加速引入报告草稿功能，使放射科医生能够以更高的准确性和标准化程度增加阅片量。这种方法将使RadNet优化内部资源利用，从而提高运营和成本效率。

This acquisition is structured as an all-cash transaction, including a post-closing milestone, and is valued at a purchase price of up to €230 million. The valuation is reflective of Gleamer’s multi-year high recurring revenue growth, cloud-native gross margins, industry-leading customer retention rates and its wide portfolio, inclusive of four FDA-cleared and six CE-marked devices supporting 25+ indications..

此次收购被设计为全现金交易，包含交割后的里程碑，估值高达2.3亿欧元。该估值反映了Gleamer多年来的高经常性收入增长、云原生的高毛利率、行业领先的客户留存率及其广泛的产品组合，包括四款获FDA批准和六款获CE认证的设备，支持25种以上的适应症。

Media Event and European Congress of Radiology Details

媒体活动和欧洲放射学大会详情

RadNet and DeepHealth will hold a dedicated media event on Monday, March 2, at 1 p.m. Eastern Time / 10 a.m. Pacific Time/ 7 p.m. Central European Time, to further expand on this announcement. Journalists are invited to participate using this link -

RadNet 和 DeepHealth 将于东部时间 3 月 2 日（星期一）下午 1 点/太平洋时间上午 10 点/欧洲中部时间晚上 7 点举行专门的媒体活动，以进一步详细说明此公告。记者可使用此链接参与：-

https://edge.media-server.com/mmc/p/4pza4nct/

https://edge.media-server.com/mmc/p/4pza4nct/

.

。

DeepHealth will be showcasing its comprehensive integrated portfolio of native solutions and services this week at the European Congress of Radiology (ECR) 2026, taking place in Vienna, between March 4-7, 2026, at Booth #506 in Hall X5.

DeepHealth 将于 2026 年 3 月 4 日至 7 日在维也纳举行的 2026 年欧洲放射学大会 (ECR) 上，在 X5 展厅 #506 展位展示其全面的原生解决方案和服务组合。

Investor Call Details

投资者电话会议详情

On Thursday, March 5, 2026, investors are invited to join a dedicated conference call and presentation to hear more details about the Gleamer transaction and have the opportunity to ask questions at 7:30 a.m. Pacific Time / 10:30 am. Eastern Time / 4:30 p.m. Central European Time by dialing 1-877-300-8521.

2026年3月5日星期四，投资者受邀参加专门的电话会议和报告会，听取有关Gleamer交易的更多细节，并有机会在太平洋时间上午7:30/东部时间上午10:30/欧洲中部时间下午4:30通过拨打1-877-300-8521提问。

International callers can dial 1-412-317-6026. There will also be simultaneous and archived webcasts available at .

国际呼叫者可拨打 1-412-317-6026。还将提供同步和存档的网络广播，访问地址为 。

https://viavid.webcasts.com/starthere.jsp?ei=1754074&tp_key=f33cfae0ea

https://viavid.webcasts.com/starthere.jsp?ei=1754074&tp_key=f33cfae0ea

[viavid.webcasts.com]. An archived replay of the call will also be available and can be accessed by dialing 1-844-512-2921 from the U.S., or 1-412-317-6671 for international callers using the passcode: 10207004

[viavid.webcasts.com]。此次电话会议的存档重播也将提供，美国境内可拨打1-844-512-2921，国际来电请拨打1-412-317-6671，并使用密码：10207004访问。

About RadNet, Inc.

关于RadNet公司

RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of owned and/or operated outpatient imaging centers. RadNet’s markets include Arizona, California, Delaware, Florida, Indiana, Maryland, New Jersey, New York and Texas.

RadNet, Inc. 是美国基于地点数量和年度影像收入的领先的全国性独立固定诊断影像服务提供商。RadNet 拥有并/或运营门诊影像中心的网络。RadNet 的市场包括亚利桑那州、加利福尼亚州、特拉华州、佛罗里达州、印第安纳州、马里兰州、新泽西州、纽约州和德克萨斯州。

In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has over 11,000 team members.

此外，RadNet 还提供放射学信息技术和人工智能解决方案，这些方案以 DeepHealth 品牌销售，并为诊断影像行业的客户提供远程放射学专业服务及其他相关产品和服务。RadNet 与签约放射科医生一起，包括全职和按日计薪的员工及技术人员，拥有超过 11,000 名团队成员。

Learn more at .

了解更多，请访问。

radnet.com

radnet.com

.

。

About DeepHealth

关于DeepHealth

DeepHealth is a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT) and serves as the umbrella brand for RadNet’s Digital Health segment. DeepHealth provides AI-powered health informatics with the aim of empowering breakthroughs in care through imaging.

DeepHealth 是 RadNet, Inc.（纳斯达克股票代码：RDNT）的全资子公司，作为 RadNet 数字健康部门的旗舰品牌。DeepHealth 提供人工智能驱动的健康信息学，旨在通过影像技术推动护理领域的突破。

DeepHealth leverages advanced AI for operational efficiency and improved clinical outcomes in breast, chest, neuro, prostate and thyroid health. At the heart of DeepHealth’s portfolio is a cloud-first operating system – DeepHealth OS – that unifies data across the clinical and operational workflow and personalizes AI-powered workspaces for everyone in the radiology continuum.

DeepHealth 利用先进的人工智能技术，提升乳腺、胸部、神经、前列腺和甲状腺健康领域的运营效率及临床效果。DeepHealth 产品组合的核心是一个以云为先的操作系统——DeepHealth OS，该系统统一了临床和运营工作流程中的数据，并为放射学领域的每个人提供个性化的 AI 工作空间。

Thousands of imaging centers and radiology departments around the world use DeepHealth solutions to enable earlier, more reliable and more efficient disease detection, including in large-scale cancer screening programs. DeepHealth’s human-centered, intuitive technology aims to push the boundaries of what’s possible in healthcare.

全球成千上万的影像中心和放射科部门使用DeepHealth解决方案，以实现更早、更可靠和更高效的疾病检测，包括在大规模癌症筛查项目中。DeepHealth以人为本、直观的技术旨在突破医疗保健领域的可能性界限。

.

。

https://deephealth.com

https://deephealth.com

About Gleamer

关于Gleamer

Founded in 2017, Gleamer considers AI to be a key solution for addressing the sharp rise in demand for medical imaging, stemming from the challenges of an ageing population, the increasing prevalence of chronic diseases and the problems of access to healthcare. The company's suite of AI-powered solutions, across X-ray, mammography, CT and now, MRI, supports radiologists and clinicians in their diagnoses, thereby improving reliability and reducing the time taken to read and process examinations.

Gleamer成立于2017年，认为人工智能是应对医学影像需求激增的关键解决方案，这一需求源于人口老龄化、慢性病患病率不断上升以及医疗资源获取问题等挑战。该公司提供一系列基于人工智能的解决方案，涵盖X光、乳腺摄影、CT，现在还包括MRI，支持放射科医生和临床医生进行诊断，从而提高诊断可靠性并缩短读片和处理检查的时间。

The relevance and exceptional performance of these solutions have been recognized worldwide thanks to 60 publications in highly regarded peer-reviewed journals. With 30+ million exams analyzed across over 2,250 locations, spanning 44 countries, Gleamer’s solutions are now widely acclaimed within the medical imaging industry.

这些解决方案的相关性和卓越性能已获得全球认可，这得益于在备受推崇的同行评审期刊上发表的60篇论文。通过对44个国家、2250多个地点的3000多万次考试进行分析，Gleamer的解决方案现在已在医学影像行业广受赞誉。

.

。

www.Gleamer.ai

www.Gleamer.ai

.

。

Forward-Looking Statements

前瞻性声明

This communication contains certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “outlook,” “plan,” “potential,” “possible,” “predict,” “project,” “seek, “should,” “target,” “will” or “would,” the negative of these words, and similar references to future periods.

本通讯包含某些“前瞻性声明”，这些声明符合1995年美国私人证券诉讼改革法案、经修订的1933年证券法第27A条以及经修订的1934年证券交易法第21E条中的安全港条款。前瞻性声明可以通过以下词语来识别：“预期”、“相信”、“可能”、“估计”、“预计”、“预测”、“打算”、“也许”、“展望”、“计划”、“潜力”、“可能”、“推测”、“项目”、“寻求”、“应该”、“目标”、“将”或“会”，以及这些词语的否定形式和对未来期间的类似提及。

Examples of forward-looking statements include statements regarding the anticipated benefits of the acquisition, the impact of the acquisition on RadNet’s business and future financial and operating results and prospects and the amount and timing of synergies from the acquisition are based on the current estimates, assumptions and projections of RadNet, and are qualified by the inherent risks and uncertainties surrounding future expectations generally, all of which are subject to change.

前瞻性陈述的示例包括关于收购预期收益的陈述、收购对RadNet业务及未来财务和运营结果与前景的影响，以及收购协同效应的规模和时间的陈述，这些均基于RadNet当前的估算、假设和预测，并受制于围绕未来预期的一般性固有风险和不确定性，所有这些都可能发生变化。

Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties, many of which are beyond RadNet’s control..

实际结果可能与当前预期有很大差异，原因是存在许多风险和不确定性，其中很多是RadNet无法控制的。

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management’s current beliefs, expectations and assumptions regarding the future of RadNet’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions.

前瞻性声明既不是历史事实，也不能保证未来的表现。相反，它们仅基于管理层对RadNet业务未来、未来计划和战略、预测、预期事件和趋势、经济状况及其他未来条件的当前信念、期望和假设。

Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of RadNet’s control. RadNet’s actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors.

由于前瞻性陈述涉及未来，它们受固有的不确定性、风险和难以预测的环境变化的影响，其中许多因素是RadNet无法控制的。RadNet的实际结果和财务状况可能因各种因素而与前瞻性陈述中所示的内容存在重大差异。

None of RadNet, Gleamer SAS any of their respective directors, executive officers, or advisors, provide any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur, or if any of them do occur, what impact they will have on the business, results of operations or financial condition of RadNet.

RadNet、Gleamer SAS 及其各自的董事、高级管理人员或顾问均不提供任何陈述、保证或担保，无论是明示还是暗示的前瞻性陈述中所述事件是否会发生，或者即使其中某些事件确实发生，它们将对RadNet的业务、经营结果或财务状况产生何种影响。

Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on RadNet’s business and the ability to realize the expected benefits of the acquisition. Risks and uncertainties that could cause results to differ from expectations include, but are not limited to: (1) the ability to recognize the anticipated benefits of the acquisition, which may be affected by, among other things, the ability of RadNet or Gleamer SAS to maintain relationships with its vendors, customers, providers and retain its management and key employees, (2) the ability of RadNet to achieve the synergies contemplated by the acquisition or such synergies taking longe.

如果任何风险和不确定性发展为实际事件，这些情况可能会对RadNet的业务以及实现收购预期收益的能力产生重大不利影响。可能导致结果与预期不同的风险和不确定性包括但不限于：(1) 实现收购预期收益的能力，这可能受到RadNet或Gleamer SAS与其供应商、客户、提供商保持关系及保留其管理层和关键员工能力的影响；(2) RadNet实现收购预期协同效应的能力，或此类协同效应需要更长时间才能实现。

Forward-looking statements included herein are made only as of the date hereof and, except as required by applicable law, RadNet does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent.

本文件中包含的前瞻性陈述仅截至本文日期作出，除非适用法律要求，RadNet不承担更新任何前瞻性陈述或本通讯中任何其他信息的义务，无论是否因新信息、未来发展或其他原因导致这些陈述或信息出现不准确或遗漏。

All forward-looking statements in this communication are qualified in their entirety by this cautionary statement..

本通讯中所有的前瞻性陈述均受此警示性声明的全面约束。

RadNet Contacts

放射网联系人

Jane Mazur

简·马祖尔

Senior Vice President, Corporate Communications

高级副总裁，企业传播部

+1 585-355-5978

+1 585-355-5978

jane.mazur@radnet.com

简·马祖尔@radnet.com

Mark Stolper

马克·斯托尔珀

Executive Vice President and Chief Financial Officer

执行副总裁兼首席财务官

+1 310-445-2800

+1 310-445-2800

DeepHealth Media Contact

DeepHealth 媒体联系人

Andra Axente

安德拉·阿克森特

Integrated Communications Leader

综合通信领导者

+31614440971

+31614440971

andra.axente@deephealth.com

安德拉·阿克森特@深度健康.com

A photo accompanying this announcement is available at

随此公告附带的照片可在

https://www.globenewswire.com/NewsRoom/AttachmentNg/ca9b68a4-4ed1-48de-b059-dc370bc2132d

https://www.globenewswire.com/NewsRoom/AttachmentNg/ca9b68a4-4ed1-48de-b059-dc370bc2132d

i

我

The Company defines Annual Recurring Revenue (ARR) as a key subscription economy metric representing the predictable, normalized annualized value of contracted recurring revenue generated from customers from active customer contracts. ARR includes subscription fees, recurring support fees, and contracted usage charges and excludes one-time, non-recurring fees such as, implementation, hardware sales, professional services, consulting and one-off training.

公司定义年度经常性收入（ARR）为订阅经济中的一个关键指标，代表从活跃客户合同中产生的可预测的、标准化的年度经常性收入价值。ARR包括订阅费、经常性支持费和合同约定的使用费，排除一次性、非经常性费用，例如实施费、硬件销售、专业服务、咨询和一次性培训。

ARR is a non-GAAP measure and does not represent GAAP revenue recognized over time..

ARR 是非 GAAP 指标，并不代表随时间确认的 GAAP 收入。

ii

二

DeepHealth and Gleamer have a combined installed base of 2,700+ customer contracts across more than 50 countries, a comprehensive portfolio including 26 FDA-cleared and 22 CE-marked devices supporting 75+ indications, and a global footprint with 550+ employees across four continents. DeepHealth with Gleamer together anticipate achieving ARR approaching or exceeding $140 million by the end of 2026.

DeepHealth 和 Gleamer 在超过 50 个国家拥有总计 2700 多份客户合同的联合安装基础，全面的产品组合包括 26 种获得 FDA 批准和 22 种获得 CE 认证的设备，支持 75 多种适应症，并在全球四大洲拥有 550 多名员工。DeepHealth 与 Gleamer 预计到 2026 年底将实现接近或超过 1.4 亿美元的年度经常性收入 (ARR)。

We believe that these metrics make DeepHealth the leader in providing clinical radiology AI solutions worldwide..

我们相信，这些指标使DeepHealth成为全球领先的临床放射学AI解决方案提供商。